⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of BeBetter Med Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
BeBetter Med Inc.
↗Guangzhou, China
BeBetter Med is a China-based biopharmaceutical company focused on the research, development, and commercialization of innovative therapies for oncology, autoimmune diseases, and metabolic disorders. The company utilizes advanced technology platforms, including small molecule drug development, GDOC (Gene-Directed Oligonucleotide Conjugate) siRNA, and POC (Peptide-Oligonucleotide Conjugate) platforms to address high-burden diseases.
Founded in 2012 and headquartered in Guangzhou, China, the company has established a robust pipeline of candidates such as BEBT-908 (a dual HDAC/PI3Kα inhibitor) and BEBT-701 (an siRNA drug targeting AGT/PCSK9). BeBetter Med is publicly traded on the Shanghai Stock Exchange (STAR Market) under the ticker 688759.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2012
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Investors:Guangzhou Yuexiu Industrial Investment Fund Management, Shenzhen Ruixiangyuan Fund Management, Sanmei Capital, Shenzhen Lucky Source Investment Management
STOCK
Exchange:Shanghai Stock Exchange
Ticker:688759
Market Cap:$1.86B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (BEBT-908)
Modalities:Small molecule, siRNA, Oligonucleotide conjugates
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Sun Yat-sen Memorial Hospital (Clinical research collaboration)
COMPETITION
Position:Emerging
Competitors:Jazz Pharmaceuticals, Moderna, Sana Biotechnology
LEADERSHIP
Key Executives:
Changgeng Qian - CEO & Board Chairman
Yan Xiong - Vice Chairman
LINKS
Website:bebettermed.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with BeBetter Med Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.